Xcout IntelAprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Subscribe to see Aprea Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aprea Therapeutics, Inc. at a glance
Aprea Therapeutics, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (APRE) with a market capitalisation of $7.5M. Xcout tracks 32 named people at Aprea Therapeutics, Inc., including Oren Gilad, Ph.D. (President and CEO).
Aprea Therapeutics, Inc. leadership
- Oren Gilad, Ph.D.President and CEO
- John HamillSenior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary
- Eugene KennedyChief Medical Advisor
- Lars AbrahmsenSenior Vice President & Chief Scientific Officer
- Zeev WeissChief Business Advisor
- Oren GiladCo-Founder, Chief Executive Officer, President and Director
26 more named people on record for Aprea Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Aprea Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $5.7M | 8 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Aprea Therapeutics, Inc. competitors
A few of Aprea Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Artios Pharma is an independent biotechnology company headquartered at the Babraham Research Campus in Cambridge, United Kingdom, focused on discovering novel cancer therapies through DNA damage response mechanisms.
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Auron Therapeutics, Inc. is a biotechnology company headquartered in Newton, Massachusetts. The company focuses on targeting cell states to deliver next-generation targeted cancer therapies.
Pretzel Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, advancing a new class of medicines that target cellular energetics and mitochondrial function.
Get Aprea Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Aprea Therapeutics, Inc. in Xcout Intel
- 32 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access